KLKate Diana Lynch

Kate Diana Lynch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kate Diana Lynch has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis

    by Amera Elzubeir, Anjana Kumar, Alistair McArdle, Emily Holden, Leo Alexandre, Simon Rushbrook, Kate D. Lynch

    Background: Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD). Data on the safety and effectiveness of advanced IBD therapies on IBD outcomes in PSC‐IBD remain limited. Methods: A systematic review and meta‐analysis assessed the safety and effectiveness of advanced therapies in adults with PSC‐IBD. MEDLINE, Embase, Cochrane databases and Web of Science were searched to July 2026. The primary outcome was IBD clinical remission. Secondary outcomes included clinical response, corticosteroid‐free remission, mucosal healing, adverse event‐related treatment discontinuation and colorectal neoplasia. A random‐effects model was used for pooled estimates. Results: Five retrospective case‐series ( n = 394) evaluating infliximab, adalimumab, vedolizumab and tofacitinib were included (median follow‐up of 18.4 months). Pooled clinical remission rates were 24.7% (95% CI: 17.2%–33.0%) at 3 months and 28.6% (95% CI: 16.3%–42.6%) at 6–12 months. Corticosteroid‐free remission was achieved in 45.4% (95% CI: 33.1%–57.9%) and mucosal healing in 25.6% (95% CI: 13.6%–39.5%). Tofacitinib was associated with a clinical response rate of 59.3% (95% CI: 40.0%–77.2%) and low adverse event rate, in a single available study. Adverse event‐related discontinuation occurred in 9.1% (95% CI: 4.4%–15.1%), while 31.8% (95% CI: 25.5%–38.5%) experienced primary non‐response or secondary loss of response. The pooled proportion of colorectal neoplasia was 10.5% (12/112; 95% CI: 5.3%–17.1%). Five patients developed colorectal cancer (5/112; 4.3%) and two (2/177; 0.8%) cholangiocarcinoma. Conclusion: Advanced IBD therapies demonstrate modest but encouraging effectiveness and an acceptable safety profile in PSC‐IBD; however, the available evidence is limited by retrospective study designs, small sample sizes and substantial clinical and methodological heterogeneity. Prospective controlled studies using standardised IBD outcomes are needed to inform optimal therapeutic strategies in this high‐risk population. Trial Registration: PROSPERO: CRD42024580296


  • Open Access

    The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort

    by Sreecanth S. Raja, Samuel P. Costello, Alexandra Sadler, Nicholas Wan, Bhuwan Tandon, Dharshan Sathananthan, Kate D. Lynch, Chris K. Rayner, Suzanne Edwards, Robert V. Bryant

    Background: Despite limited extent, patients with ulcerative proctitis (UP) can suffer from debilitating symptoms, complications, and risk of disease extension. The aim was to provide a contemporary real‐world insight into the management and outcomes of UP. Methods: A retrospective cohort study was conducted of UP patients attending three tertiary hospitals in Adelaide, South Australia, between 2015 and 2024. Demographic, treatment, and disease‐related data were captured. Treatment success was defined as clinical response at last follow up. The primary outcome was the development of disease‐related complications. Results: Of 185 patients with UP, 60.5% were female, mean age at diagnosis was 41.1 years (±14.2) and median duration of follow up was 4.18 years (IQR 2.0–7.3 years). Most patients ( n = 114, 62.3%) achieved treatment success with 5‐ASA therapy, but one third ( n = 56, 30.3%) developed refractory UP. For those with refractory UP, treatment success was achieved in 45% of patients using systemic immunomodulators ( n = 40) and in 59% using advanced therapies ( n = 27). Topical tacrolimus was used in 10 patients, of whom three achieved treatment success. Overall, 34 patients (18.4%) developed either proximal disease extension ( n = 22, 11.9%) or traditional UC related complications including hospitalization ( n = 15, 8.1%) and colectomy ( n = 1, 0.05%). The presence of refractory UP was associated with development of traditional UC related complications ( p < 0.0001). Conclusion: Despite a short segment of inflammation, UP remains a clinical conundrum as many patients develop refractory disease, disease extension, and complications. Further prospective studies are required to define optimal therapeutic strategies for this under‐recognized cohort.

  • Corticosteroid therapy following infliximab rescue in acute severe ulcerative colitis: should they be continued?

    by Benjamin Ngoi, Tuan Anh Duong, Robert V. Bryant, Jane M. Andrews, Kate D. Lynch

    In patients with acute severe ulcerative colitis (ASUC) who have received infliximab rescue therapy, the need for and timing of further steroid therapy is unclear. This brief communication explores contemporary clinical practice across Australia regarding corticosteroid management following rescue therapy in ASUC. By describing variability in real‐world practice patterns and potential risks and benefits of different approaches, this article highlights current evidence gaps and the need for further studies to better inform clinical practice.

  • Open Access

    Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations

    by Eun Soo Kim, Dong Hyun Kim, Seong-Jung Kim, Sang Hyoung Park, Hyun Seok Lee, Sung Kook Kim, Hyun Soo Kim, Jun Lee, Kyeong Ok Kim, Byung Ik Jang, et al.

    Background: This study aimed to develop predictive models for acute severe ulcerative colitis (ASUC) using data from East Asian (EA) patients and to validate their performance in an Australia/New Zealand (ANZ) cohort. Methods: A retrospective international study was conducted across 23 referral hospitals in EA and ANZ, enrolling consecutive ASUC patients between January 2015 and December 2022. Logistic regression analyses were used to construct predictive models for 1-year colectomy and non-response to corticosteroid therapy (NRS). Results: Overall, 826 patients with ASUC were included (411 EA and 415 ANZ). Among EA patients, independent predictors of 1-year colectomy included female sex, prior exposure to tumor necrosis factor inhibitors, and admission albumin ≤3 g/dL. Independent predictors of NRS in the EA cohort were age at diagnosis ≤37 years, baseline steroid use, admission albumin ≤2.5 g/dL, and the presence of extraintestinal manifestations. The EA-derived scoring systems demonstrated strong predictive performance within the EA cohort (1-year colectomy: P < .0001; NRS: P = .001) but showed limited utility in the ANZ cohort (P = .106 and P = .012). In contrast, European-developed models—including the French 1-year colectomy score and the ADMIT-ASC index for NRS—accurately predicted outcomes in the ANZ cohort (P = .007 and P < .0001) but had reduced predictive capacity in the EA cohort (P = .106 and P = .026). These findings were consistent in both cohorts following propensity score matching. Conclusions: Predictive factors for ASUC differ substantially between EA and ANZ patients, highlighting the need for population-specific predictive tools.

  • Open Access

    Recurrent Cryptogenic Ulcerative Tracheobronchitis 6 Years After Lung Transplantation: Case Report

    by Samuel Brookes, Paroma Sarkar, Thomas Crowhurst, Phan Nguyen, Aeneas Yeo, Kate D. Lynch, Helen Whitford, Mark Holmes, Chien-Li Holmes-Liew

    Background: Tracheobronchitis is an uncommon pattern of airway disease and is typically caused by infection, inhalation injury, infiltrative disorders and more rarely, systemic autoimmune disease. Rarer again is the development of bronchial webbing following tracheobronchitis. The underlying aetiology is usually identified through biopsy, culture or a detailed clinical history. We present a case of cryptogenic ulcerative tracheobronchitis with bronchial webbing being successfully managed by bilateral lung transplantation that has, however, been complicated by recurrence. Case Presentation: In 2019, Crowhurst et al. detailed the case of a patient who presented with dyspnoea and haemoptysis. Bronchoscopy revealed ulcerative tracheobronchitis and he subsequently formed recurrent web‐like stenoses of the central bronchi, leading to rapidly progressive type 2 respiratory failure; he received bilateral sequential lung transplantation for definitive management. At the time of transplant, the presumed diagnosis was an inhalation injury that occurred while travelling in Vietnam, or exposure to the organophosphate pesticide Malathion several days prior. The explanted lung histology revealed ulcerating bronchitis with intense histiocytic infiltrates, bronchial luminal fibrosis and obstruction with scant, poorly formed granulomas. The patient thrived with stable lung function and had minimal complications initially post‐transplantation. However, 6 years after lung transplantation and without re‐exposure, the patient re‐developed ulcerative tracheobronchitis, which shared similar histopathologic features to airway involvement of Crohn’s disease. Gastrointestinal or other organ system involvement of Crohn’s disease was not established despite extensive investigations. A decision for phenotypic treatment with the TNF‐ α inhibitor, infliximab, was made with subsequent rapid improvement in the tracheobronchitis. Conclusion: This is the first case documented in the literature of ulcerative tracheobronchitis followed by intense bronchial web‐like stenoses caused by an unspecified autoimmune disease, treated by bilateral lung transplantation. The disease recurred after 6 years and responded to phenotypic management with the TNF‐ α inhibitor, infliximab. The patient will require careful monitoring given the risk of augmented immunosuppression and unknown disease trajectory.

  • Open Access

    Navigating the Hepatic Immune Landscape With Fine Needle Aspiration of the Liver—An Emerging Technique

    by Kate Diana Lynch, Fabiola Curion, Hing‐Yuen Yeung, Charlotte Rich‐Griffin, Devika Agarwal, Helen Ferry, Andrew Slater, Emma Louise Culver, Roger William Chapman, Satish Keshav, et al.

    Background and Aims: Hepatic immune cell analysis is critical for understanding chronic inflammatory liver diseases, such as primary sclerosing cholangitis (PSC) and steatotic liver disease. However, liver immunoprofiling is limited due to reliance on end‐stage disease liver explants. Fine needle aspiration (FNA) is a minimally invasive technique that can overcome these limitations. We evaluate the safety and efficacy of liver FNA to profile hepatic immune subsets in non‐infectious liver conditions. Methods: Flow cytometry and single‐cell RNA sequencing (scRNA‐seq) were used to compare the hepatic immune cell composition and gene expression to that of matched peripheral blood mononuclear cells (PBMCs). Results: We obtained liver FNAs from 38 patients. The median pain score was 0. No serious adverse effects were reported. Flow cytometry demonstrated enrichment of CD69 + T and natural killer (NK) cells in the liver (all P adj < 0.05). ScRNA‐seq of 38 012 hepatic immune cells and 78 751 PBMCs in a patient subset showed specific enrichment of CXCR6 + NK, CD8 + central memory T, and mucosal‐associated invariant T (MAIT) cells in the liver, and relatively lower CD4 + regulatory T cell (Treg) abundance (all P adj < 0.05). Gene expression and cell–cell interaction analyses revealed increases in cytokine production, signalling, and responsiveness in hepatic immune cells compared to PBMCs. Conclusions: FNA sampling is a safe approach for investigating the inflammatory landscape of PSC and other liver diseases. Single‐cell profiling reveals that FNAs capture tissue‐specific immune cell types and gene expression differences, suggesting this sampling method may provide a basis for future experimental medicine analyses.

  • Open Access

    Stomal calprotectin as a biomarker for assessing Crohn disease activity in patients with stomas

    by Kavindra Abeyratne, Martin Harb, Karen Bensted, Simon Ghaly, Susan J. Connor, Jane M. Andrews, Kate D. Lynch

    Background: Faecal calprotectin is a reliable biomarker for lower gastrointestinal inflammation. However, there are limited data on the utility of calprotectin from stoma effluent.Aim: The aim of this study was to determine the performance of stomal calprotectin in identifying Crohn disease activity in those with a stoma.Methods: Patients with Crohn disease and an ileostomy or colostomy were identified from three sites in Australia using a clinical management software. Disease activity was classified based on the presence of inflammation on imaging and/or endoscopy within 3 months of the sample. The primary outcome was the median stomal calprotectin in people with active versus inactive Crohn disease. Other clinical indices, such as C‐reactive protein and Harvey Bradshaw Index, were evaluated as a surrogate biomarker for disease activity.Results: Thirty stomal calprotectin results were identified for 23 patients with paired investigations. Of 30 cases, six had active disease. The median stomal calprotectin in active versus inactive disease were 17 μg/g (interquartile range (IQR) 5–211) and 61 μg/g (IQR 19–105, P = 0.38) respectively. Accordingly, stomal calprotectin demonstrated poor sensitivity for active disease (33% at cut‐off of 50 μg/g). C‐reactive protein was higher for active disease (25, IQR 5–199) compared with inactive disease (5, IQR 2–17, P = 0.06), but there was no difference in the Harvey Bradshaw Index (9 (IQR 7–11) vs 5 (3–7), P = 0.10).Conclusion: Stomal calprotectin did not reliably distinguish between active and inactive Crohn disease. C‐reactive protein is a more reliable biomarker for disease activity in the setting of ileostomy/colostomy. Further prospective studies are needed to identify more robust biomarkers for detecting inflammation in stoma patients.


  • Open Access

    Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial

    by Robert D Little, Jo McKenzie, Ashish Srinivasan, Patrick Hilley, Robert B Gilmore, Desmond Chee, Manjeet Sandhu, Daniel Saitta, Elizabeth Chow, Lena Thin, et al.

    Introduction A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional intravenous infliximab is labour-intensive and expensive, depending on insurance and pharmaceutical reimbursement. Observational data suggest that subcutaneous infliximab may offer a convenient and safe alternative to maintain disease remission in patients requiring dose-intensified infliximab. A prospective, controlled trial is required to confirm that subcutaneous infliximab is as effective as dose-intensified intravenous infliximab, to identify predictors of disease flare and to establish the role of subcutaneous infliximab therapeutic drug monitoring. Methods and analysis The DISCUS-IBD trial is an investigator-initiated, prospective, multicentre, randomised, open-label non-inferiority study comparing the rate of disease flares in participants randomised to continue dose-intensified intravenous infliximab to those switched to subcutaneous infliximab after 48 weeks. Participants are adult patients with IBD in sustained corticosteroid-free remission on any regimen of dose-intensified infliximab up to a maximum of 10 mg/kg 4-weekly intravenously. Participants allocated to intravenous infliximab will continue infliximab at the same dose-intensified regimen they were receiving at study enrolment. Subcutaneous infliximab dosing will be stratified by prior intravenous infliximab dosing. Clinical (Harvey-Bradshaw Index, partial Mayo score), biochemical (C reactive protein, faecal calprotectin), pharmacokinetic (drug-level±antidrug antibodies) and qualitative data are collected 12-weekly until study conclusion at week 48. 13 sites across Australia will participate in recruitment to reach a calculated sample size of 120 participants. Ethics and dissemination Multisite ethics approval was obtained from the Health District Human Research Ethics Committee (HREC) at The Alfred Hospital under a National Mutual Acceptance (NMA) agreement (HREC/90559/Alfred-2022; Local Reference: Project 618/22, version 1.6, 2 March 2023). Findings will be reported at national and international gastroenterology meetings and published in peer-reviewed journals. DISCUS-IBD was prospectively registered with the Australian and New Zealand Clinical Trials Registry (ANZCTR) prior to commencing recruitment. Trial registration number ACTRN12622001458729.